The mRESV by Moderna. An mRNA RSV vaccine candidate for older adults

mRESV, Moderna’s investigational mRNA RSV vaccine for adults 60 and over, is moving through late-stage trials with a clear focus on respiratory season protection. The Moderna Inc. stock (ISIN US60770K1079) benefits from this product line.

mRESV, Moderna’s investigational RSV vaccine candidate, sits in a stainless steel tray under harsh white trial-site lights, its clear solution catching a faint reflection of a research nurse’s blue glove. Each vial in this program could represent one older adult hoping to avoid a winter in hospital.

mRNA approach against RSV

Moderna Inc. is developing mRESV as an mRNA-based vaccine targeting respiratory syncytial virus (RSV) in adults aged 60 years and older. The candidate builds on the same core mRNA platform used for its COVID-19 vaccine Spikevax, but encodes stabilized RSV F glycoprotein antigens rather than coronavirus spike. Moderna highlights the program under its respiratory portfolio, alongside influenza and COVID, in its pipeline overview.

RSV is a seasonal respiratory virus that can cause lower respiratory tract disease, particularly dangerous for older adults and those with underlying conditions. The virus leads to bronchiolitis and pneumonia, and is a major cause of hospitalizations in people over 60. According to clinical background information shared in vaccine trial announcements, severe RSV disease often presents with shortness of breath, wheezing and persistent cough.

Trial design and target group

mRESV is currently being evaluated in a pivotal Phase 3 study enrolling adult volunteers aged 60 and above in multiple countries. The study follows a randomized, observer-blind, placebo-controlled design, testing a single intramuscular dose prior to RSV season with endpoints focused on prevention of RSV-associated lower respiratory tract disease. Volunteers in the trial receive the shot in the upper arm, similar to standard influenza vaccination practice.

Chief Executive Officer Stéphane Bancel has repeatedly pointed to RSV in earnings calls as a core near-term opportunity for Moderna’s respiratory vaccine franchise. In pipeline updates, the RSV program is labeled mRNA-1345, which corresponds to mRESV in clinical documentation, and is positioned as a product candidate for high-risk older adults. Bancel has stressed the importance of protecting seniors who may already be taking multiple medications, noting that a once-per-season shot is more realistic than frequent dosing.

Positioning against rival RSV vaccines

Moderna’s mRESV program sits in a competitive field where traditional RSV vaccines from GSK and Pfizer are already approved for older adults. GSK’s Arexvy and Pfizer’s Abrysvo use protein-based approaches and have been cleared by regulators in the United States and Europe. Moderna aims to differentiate mRESV through its mRNA technology, potentially offering flexible strain updates and combination options with influenza or COVID vaccines. The company has discussed pursuing combination respiratory vaccines in presentations, signaling that a future older adult shot could pack RSV, flu and SARS-CoV-2 antigens into one injection.

In the lab, Moderna scientists have described mRNA constructs that instruct cells at the injection site to produce RSV antigens in situ. This transient antigen production is intended to trigger B-cell and T-cell responses without using live virus or traditional adjuvants. By fine-tuning mRNA sequence and lipid nanoparticle formulation, the team hopes to achieve strong immunogenicity with acceptable reactogenicity, a key concern in frail senior populations. Clinical staff at trial sites report typical post-vaccination sensations such as soreness at the injection site and mild fatigue, similar to flu shots, but severe adverse events are being tracked closely through formal safety monitoring.

Dosing, seasonality and logistics

For now, mRESV is tested as a single pre-season dose, given ahead of expected RSV circulation peaks. Trial documentation indicates administration in autumn months so that participants have antibody protection during winter, when RSV activity typically rises. This schedule resembles influenza vaccination patterns and reduces operational complexity for clinics already running seasonal immunization campaigns.

Moderna has outlined in investor presentations that commercial mRESV, if approved, would likely be offered through pharmacies, primary care practices and dedicated vaccination centers. From a logistics perspective, the company’s existing cold-chain infrastructure, built out during Spikevax’s global rollout, could support distribution of mRESV without major new investment. In practice, that means cartons of vials moving from centralized freezers into smaller vaccine refrigerators, then to the familiar metal trays seen in clinics before each day’s appointments.

Regulatory path and data readouts

mRESV’s regulatory journey hinges on demonstrating statistically significant efficacy in preventing RSV-associated lower respiratory tract disease in adults 60 and older. Moderna has flagged primary endpoints including reduction in medically attended RSV disease and hospitalizations. Interim data readouts from the Phase 3 trial are expected to inform submissions to authorities such as the U.S. Food and Drug Administration and the European Medicines Agency once predefined case numbers are reached.

Chief Medical Officer Paul Burton has underlined in previous interviews that regulators now have a clearer framework for RSV vaccines thanks to the first approvals in the class. He argues that this may streamline review of mRNA-based candidates like mRESV, provided safety and efficacy profiles are robust. Still, mRESV must pass through standard regulatory steps, including detailed review of manufacturing controls, stability data and post-marketing safety plans.

Financial impact and stock context

From the perspective of Moderna Inc., mRESV represents one pillar of a broader plan to build a portfolio of respiratory vaccines generating recurring seasonal revenue. Company presentations have suggested that RSV, influenza and COVID vaccinations for older adults could form a multi-billion-dollar annual market, with mRESV contributing alongside other products if it reaches approval. Investors watch RSV updates in earnings calls and pipeline disclosures as signals of how quickly Moderna can diversify beyond pandemic-era COVID sales. On Xetra, the Moderna Inc. stock recently traded in euro as part of this narrative, with respiratory vaccine candidates like mRESV considered a key medium-term driver.

Key facts about mRESV

• Product: mRESV (mRNA-1345) RSV vaccine candidate
• Manufacturer: Moderna Inc.
• Category: Novelty/Launch – investigational RSV vaccine
• Market launch: Not yet launched; in Phase 3 clinical development
• MSRP / Price: Not set; pricing to be determined upon potential approval
• Availability: Accessible only within clinical trials for adults aged 60 and older
• Target group: Older adults, especially those at increased risk of severe RSV disease
• Highlight / USP: Uses Moderna’s mRNA platform to target RSV, with potential for future combination respiratory vaccines